Mapmygenome Completes Acquisition of US-Based dnaPower, Building a Central DNA and Genomics Platform

The Quick Take

• Mapmygenome has completed the acquisition of dnaPower Inc., a US-based DNA health and wellness testing company.
• CEO Anu Acharya says the deal creates a central platform integrating DNA, microbiome, pharmacogenetic, and longevity testing.
• The acquisition expands Mapmygenome's international presence and builds toward a comprehensive genomics-as-a-service offering.

Mapmygenome's acquisition of dnaPower creates a cross-continental genomics platform that positions the Hyderabad-based company to compete in the rapidly growing precision medicine and consumer genomics market. The integration of dnaPower's DNA health and wellness testing capabilities with Mapmygenome's existing genomic services — including carrier screening, pharmacogenomics, and ancestry analysis — builds toward the integrated 'central platform for DNA' vision articulated by CEO Anu Acharya. This multi-modal approach, combining DNA sequencing with microbiome analysis and pharmacogenetic profiling, mirrors the strategic direction of US leaders like 23andMe and Invitae, where comprehensive multi-omics data creates deeper consumer insights and recurring data-as-a-service revenue streams.

The acquisition's financial logic rests on the genomics-as-a-service model's high margin characteristics once the initial sequencing infrastructure investment is amortised across a growing subscriber base. dnaPower's US market presence gives Mapmygenome direct access to the world's largest consumer genomics market, where regulatory approval pathways for health-related genetic testing are well-established and consumer willingness to pay for actionable health insights is the highest globally. The combination creates a dual-market strategy — India's rapidly growing middle class providing volume at lower price points, US premium customers providing revenue quality — that diversifies Mapmygenome's growth dependence on any single geography.

The forward signal to watch is the integration timeline and whether the combined entity can achieve cross-sell penetration — selling dnaPower's US customer base Mapmygenome's pharmacogenomics and disease risk tests, and selling Mapmygenome's Indian clients dnaPower's longevity-focused testing products. The regulatory variable is India's upcoming personal data protection framework, which will determine how genomic data generated in India can be stored, shared, and commercialised. The macro tailwind is growing global awareness of preventive healthcare and personalised medicine, which is driving consumer genomics adoption across markets as the cost of sequencing continues its exponential decline.

Synthesized from 1 source.